• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • Comprehensive Eye Exams
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • LASIK
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

Study finds significant variance across imaging modalities on sizes of geographic atrophy areas

Publication
Article
Optometry Times JournalJuly digital edition 2023
Volume 15
Issue 07

A single, consistent modality leads to better geographic atrophy tracking.

Medical Laboratory with Team of Scientists Working. Microbiologist Looking under Microscope and working on Computer. Developing Drugs, Gene Editing, High-Tech Biotechnology Research. Back View Shot (Adobe Stock / Gorodenkoff)

A single, consistent modality leads to better geographic atrophy tracking. (Adobe Stock / Gorodenkoff)

Fundus autofluorescence, a common imaging modality used to assess the retina, may be under-reporting the sizes of geographic atrophy across various phenotypic features, according to Noor Chahal, BS, who reported these findings at the 2023 Association for Research in Vision and Ophthalmology Annual Meeting.

Chahal and colleagues compared the results of geographic atrophy (GA) measurements obtained using color fundus photography, fundus autofluorescence, and infrared reflectance. They evaluated the agreement among measurements obtained from the imaging modalities with an emphasis on the relationship with phenotypic GA features.

Pull quote that reads: "Fundus autofluorescence may be under-reporting the sizes of geographic atrophy across various phenotypic features."

During the METforMIN clinical trial, Chahal said that he and his colleagues analyzed findings from 170 color fundus photographs, 185 fundus autofluorescence images, and 185 infrared reflectance images. The images were obtained from 128 eyes from 77 patients with GA. Two independent masked graders measured the areas of GA in the images. The fundus autofluorescence images were measured manually and semiautomatically using RegionFinder Software (Heidelberg Engineering, Inc.).

Images were then stratified based on the GA focality, homogeneity, size, and color to identify any significant differences in measurements between the semiautomatically graded fundus autofluorescence images and the other methods. Homogeneous lesions were defined as GA lesions with homogeneous hypofluorescence on fundus autofluorescence. Conversely, non-homogeneous lesions were defined as GA lesions with mixed hypo- and hyperfluorescence on fundus autofluorescence, Chahal explained.

Results of image comparisons

The measurement results of the areas of GA by modality were as follows: color fundus photographs, 9.18 ± 8.11 mm2; manually measured fundus autofluorescence images, 8.75 ± 7.32 mm2; semiautomatically graded fundus autofluorescence images, 7.02 ± 5.52 mm2; and infrared reflectance images, 8.76 ± 7.37 mm2. The investigators reported that the 4 methods had excellent intergrader agreement (intraclass correlation coefficient, > 0.99) within the same modality. The semiautomatic gradings of the fundus autofluorescence (FAF) images (7.02 ± 5.52mm2) were significantly lower than the color fundus photographs (9.18 ± 8.11mm2, P = .001), manually graded FAF (8.75 ± 7.32mm2, P = .004), and the infrared reflectance (8.76 ± 7.37mm2, P = 0.003) image measurements.

The same relationship was seen in the unifocal, multifocal, and nonhomogeneous GA lesions. However, among the 53 homogeneous GA lesions, the semiautomatically measured autofluorescence results did not differ significantly from those of the fundus photographs (difference, –0.88 ± 1.27 mm2; P = .06), manually measured autofluorescence results (difference, –0.51 ± 0.68 mm2; P = .27), and infrared reflectance results (difference, –0.45 ± 0.71 mm2; P = .21), the authors reported.

In addition, gray GA lesions (n = 5) had the highest cross-modality differences when compared to measurements obtained using semiautomated fundus autofluorescence. The measurements from the fundus photographs showed a difference of –6.29 ± 5.18 mm2. Those from the manual autofluorescence measured, –8.43 ± 1.96 mm2, and from the infrared reflectance measured, –6.41 ± 2.88 mm2.

“Although each method had excellent intergrader agreement, the GA sizes measured semiautomatically on autofluorescence images were significantly lower than in other imaging modalities,” the authors concluded. Finally, they encourage clinicians and researchers to use a single, consistent modality for disease monitoring and progression and to consider GA phenotype when interpreting imaging results.

Reference
1. Chahal, N; Shen, L L, Kennan, J, et al. Comparison of fundus photography, autofluorescence, and infrared imaging in various phenotypic features of geographic atrophy. Paper presented at: the 2023 Association for Research in Vision and Ophthalmology Annual Meeting; April 22—27, 2023; New Orleans, LA. Accessed May 23, 2023.
Related Videos
Jade Coats, OD, overviews a lecture on ocular pain and patient care
Jade Coats, OD, outlines two poster presentations she gave on a novel lipid-containing eye drop at the AOA Optometry's Meeting
Adam Alexander, OD, chats with Optometry Times about his AOA e-poster presentation on Miebo
Nazlee Zebardast, MD, MSc, overviews her ARVO 2024 presentations on glaucoma and polygenic risk scores
Edmund Tsui, MD, details what insights swept-source anterior segment OCT images may give to determining eye inflammation
Michael Chaglasian, OD, details success of new OCT device at the ARVO 2024 meeting
Emily Chew, MD, outlines her lecture that landed her the Proctor Award at ARVO 2024
Deborah Ferrington details a session on mitochondrial maintenance and retinal health in patients with AMD at ARVO 2024
Dr. John Sheppard discusses results from trials testing the efficacy of eye drops to treat dry eye disease
© 2024 MJH Life Sciences

All rights reserved.